CBD Science is increasing access to innovative treatments, by proving the safety & effectiveness of plant-based pain medicines to the National Health Service, in Real World settings.
CBD Science focuses on patients in the Real World, rather than random sample groups. This facilitates diagnoses, planning and tracking of treatment performance.
CBD Science continually monitor individual burden & clinical interventions through Real World Evidence (RWE) trials.
Fill out this form & you’ll be redirected to our investor Portal we will also email you to start the conversation.
With millions of patients going untreated for cancer related pain proving cannabis-based medicines as an alternative for successful pain treatments is needed as a matter of urgency.
CBD Science is led by former Deputy Medical Director of NHS England, Dr. M. Bewick, in addition to a diverse team with extensive experience in oncology and pharmaceutical patient access.
CBD Science produce and manufacture their medicines, in house, adhering to all pharmaceutical needs and legal requirements.
CBD Science is working with the Medicines Healthcare Regulatory Agency (MHRA), North-West EHealth (NWEH), National Institute for Health Research (NIHR), and the National Cancer Research Institute (NCRI).